Financial Snapshot

Revenue
$0.00
TTM
Gross Margin
Net Earnings
-$18.19M
TTM
Current Assets
Q4 2024
Current Liabilities
Q4 2024
Current Ratio
140.8%
Q4 2024
Total Assets
Q4 2024
Total Liabilities
Q4 2024
Book Value
-$4.081M
Q4 2024
Cash
Q4 2024
P/E
-3.615
Nov 29, 2024 EST
Free Cash Flow
-$9.433M
TTM

Revenues

Revenues

Revenue YoY Change

Revenues

Concept 2024 2023 2022 2021 2020 2019 2018 2017 2016
Revenue $0.00 $0.00 $0.00 $0.00 $37.00K $869.0K $508.0K $0.00
YoY Change -100.0% -95.74% 71.06%

Expenses

Cost Of Revenues

No data

Gross Profit

No data

Gross Profit Margin

No data

Gross Profit

Concept 2024 2023 2022 2021 2020 2019 2018 2017 2016
Revenue $0.00 $0.00 $0.00 $0.00 $37.00K $869.0K $508.0K $0.00
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

No data

R&D To Gross Profit Ratio

No data

DDA To Gross Profit Ratio

No data

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept 2024 2023 2022 2021 2020 2019 2018 2017 2016
Selling, General & Admin $7.476M $12.77M $13.83M $11.05M $11.28M $8.780M $4.460M $3.260M
YoY Change -41.44% -7.66% 25.11% -2.04% 28.47% 96.86% 36.81%
% of Gross Profit
Research & Development $10.46M $39.99M $17.62M $10.71M $21.07M $90.77M $68.65M $25.50M $10.10M
YoY Change -73.85% 127.01% 64.46% -49.17% -76.78% 32.23% 169.21% 152.44%
% of Gross Profit
Depreciation & Amortization $30.00K $1.750M $84.00K $391.0K $161.0K $152.0K $136.0K $65.00K $0.00
YoY Change -98.29% 1983.33% -78.52% 142.86% 5.92% 11.76% 109.23%
% of Gross Profit
Operating Expenses $18.70M $47.47M $30.38M $24.54M $32.13M $102.1M $77.43M $29.96M $13.36M
YoY Change -60.61% 56.23% 23.83% -23.62% -68.52% 31.81% 158.41% 124.29%
Operating Profit -$18.70M -$47.47M -$30.38M -$24.54M -$32.13M -$102.0M -$76.56M -$29.46M -$13.36M
YoY Change -60.61% 56.23% 23.83% -23.62% -68.51% 33.26% 159.92% 120.49%

Interest Expenses

Interest Expenses To Operating Income %

No data

Other Expense/Income

Interest & Other Expense/Income

Concept 2024 2023 2022 2021 2020 2019 2018 2017 2016
Interest Expense -$2.522M $9.628M -$2.361M -$5.553M -$15.10M -$861.0K -$426.0K $277.0K $0.00
YoY Change -126.19% -507.79% -57.48% -63.22% 1653.43% 102.11% -253.79%
% of Operating Profit
Other Income/Expense, Net -$5.838M $82.00K -$13.75M $195.0K -$19.14M -$665.0K -$25.00K $493.0K $8.000K
YoY Change -7219.51% -100.6% -7151.28% -101.02% 2777.74% 2560.0% -105.07% 6062.5%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

No data

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept 2024 2023 2022 2021 2020 2019 2018 2017 2016
Pretax Income -$24.53M -$37.76M -$44.13M -$90.86M -$51.26M -$102.7M -$76.58M -$28.96M -$13.35M
YoY Change -35.02% -14.44% -51.43% 77.24% -50.08% 34.08% 164.43% 116.93%
Income Tax $240.0K $613.0K $301.0K $705.0K $743.0K $444.0K $472.0K $444.0K $113.0K
% Of Pretax Income
Net Earnings -$24.77M -$38.37M -$44.43M -$91.56M -$91.56M -$103.1M -$77.06M -$29.41M -$13.46M
YoY Change -35.44% -13.64% -51.47% 0.0% -11.21% 33.84% 162.04% 118.4%
Net Earnings / Revenue -278729.73% -8867.2% -5788.58%
Basic Earnings Per Share -$1.26 -$2.96 -$3.63 -$8.41 -$32.49
Diluted Earnings Per Share -$1.26 -$2.96 -$3.63 -$8.407M -$2.166M -$7.103M -$5.363M -$2.238M -$1.024M

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

No data

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

No data

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept 2024 2023 2022 2021 2020 2019 2018 2017 2016
Cash & Short-Term Investments $23.93M $60.84M $81.38M $16.87M $5.940M $85.51M $40.56M $25.21M
YoY Change -60.67% -25.24% 382.4% 184.01% -93.05% 110.82% 60.89%
Cash & Equivalents $6.071M $21.09M $27.45M $14.51M $4.800M $44.55M $8.490M $24.81M
Short-Term Investments $17.86M $39.75M $53.94M $2.360M $1.140M $40.96M $32.08M $400.0K
Other Short-Term Assets $1.628M $1.210M $1.520M $4.540M $5.710M $7.140M $3.230M $400.0K
YoY Change 34.55% -20.39% -66.52% -20.49% -20.03% 121.05% 707.5%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $25.60M $62.44M $83.27M $21.47M $11.72M $92.97M $44.17M $25.86M
YoY Change -59.01% -25.01% 287.82% 83.19% -87.39% 110.48% 70.8%
Property, Plant & Equipment $600.0K $1.839M $3.832M $5.680M $7.720M $700.0K $750.0K $0.00
YoY Change -67.37% -52.01% -32.54% -26.42% 1002.86% -6.67%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $63.00K $831.0K $976.0K $5.640M $6.320M $4.200M $1.840M $1.060M
YoY Change -92.42% -14.86% -82.7% -10.76% 50.48% 128.26% 73.58%
Total Long-Term Assets $663.0K $4.389M $8.243M $11.32M $14.03M $4.900M $2.590M $1.060M
YoY Change -84.89% -46.75% -27.18% -19.32% 186.33% 89.19% 144.34%
Total Assets $26.26M $66.83M $91.51M $32.79M $25.75M $97.87M $46.76M $26.92M
YoY Change
Accounts Payable $4.996M $2.774M $878.0K $820.0K $15.49M $4.040M $3.150M $1.480M
YoY Change 80.1% 215.95% 7.07% -94.71% 283.42% 28.25% 112.84%
Accrued Expenses $8.126M $4.678M $1.629M $2.400M $13.04M $7.050M $3.970M $2.740M
YoY Change 73.71% 187.17% -32.13% -81.6% 84.96% 77.58% 44.89%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $1.627M $6.490M $5.800M $1.020M
YoY Change -100.0% -74.93% 11.9% 468.63%
Total Short-Term Liabilities $13.52M $9.064M $12.94M $41.70M $36.99M $12.22M $7.130M $4.220M
YoY Change 49.14% -29.96% -68.97% 12.73% 202.7% 71.39% 68.96%
Long-Term Debt $18.96M $28.47M $24.90M $35.85M $7.630M $13.08M $0.00 $0.00
YoY Change -33.41% 14.33% -30.55% 369.86% -41.67%
Other Long-Term Liabilities $188.0K $1.304M $3.436M $5.800M $7.380M $950.0K $80.00K $0.00
YoY Change -85.58% -62.05% -40.76% -21.41% 676.84% 1087.5%
Total Long-Term Liabilities $19.14M $29.77M $28.33M $41.65M $15.01M $14.03M $80.00K $0.00
YoY Change -35.69% 5.07% -31.97% 177.48% 6.99% 17437.5%
Total Liabilities $32.66M $38.83M $41.28M $83.35M $51.99M $26.25M $7.210M $4.220M
YoY Change -15.89% -5.91% -50.48% 60.32% 98.06% 264.08% 70.85%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

No data

Treasury Stock Shares

No data

Stock Issuance & Repurchase

Ownership Data

Concept 2024 2023 2022 2021 2020 2019 2018 2017 2016
Basic Shares Outstanding 19.70M 12.96M 12.24M 10.89M 1.601M
Diluted Shares Outstanding 19.70M 12.96M 12.24M 10.89M 1.601M
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Dividends

No data

Stock Price

Market Cap: $65.763 Million

About Iterum Therapeutics plc

Iterum Therapeutics Plc operates as a pharmaceutical company, which engages in the development and commercialization of sulopenem. The company is headquartered in Dublin, Dublin and currently employs 14 full-time employees. The company went IPO on 2018-05-25. The firm develops differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. The company is advancing its first compound, sulopenem, a novel penem anti-infective compound, in Phase III clinical development with an oral formulation. Sulopenem is a potent, thiopenem antibiotic delivered intravenously, which is active against bacteria that belong to the group of organisms known as gram-negatives and causes urinary tract and intra-abdominal infections. The company has also developed sulopenem in an oral tablet formulation, sulopenem etzadroxil-probenecid. Sulopenem also has an IV formulation. Sulopenem has demonstrated potent in vitro activity against a variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics.

Industry: Pharmaceutical Preparations Peers: AVADEL PHARMACEUTICALS PLC Endo International plc GH Research PLC Jazz Pharmaceuticals plc Mallinckrodt plc Nabriva Therapeutics plc